Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
A Randomized, Double-Blind, Placebo-Controlled Study Of Chemotherapy Plus Cetuximab In Combination With VTX- 2337 In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck.
Protocol Number:
J13177
Phase:
Phase II
Physician:
Hyunseok Kang
Purpose:
To compare the disease response, safety, and survival of patients treated with the standard of care regimen of cisplatin or carboplatin + 5FU + cetuximab in combination with VTX-2337 to those treated with the standard of care regimen alone.
Eligibility:
-confirmed squamous cell cancer of the head and neck -locoregionally recurrent or metastatic disease -measurable disease on CT or MRI scan -good physical condition with good blood counts and organ function -no prior systemic anti-cancer therapy unless administered for locally advanced disease and completed at least 6 months prior to start -no surgery, radiation, immunotherapy, or investigational agents within 4 weeks -no active autoimmune disease or known infection with HIV -no treatment with steroids with 2 weeks -no significant heart disease within 6 months prior to start -nasopharyngeal, salivary gland, lip, and sinonasal cancers are not allowed
Treatment:
Standard of care regimen is given every 21 days for a maximum 6 cycles and consists of the following: Cisplatin or Carboplatin given IV on Day 1 of each cycle. 5FU given as a continuous IV infusion via portable pump, on Days 1-4 of each cycle. Cetuximab given IV weekly. Patents will be randomized to receive VTX-2337 or Placebo given as a subcutaneous injection on Day 8 and Day 15 of each 21 day cycle. Following 6 cycles of combination therapy, VTX-2337 or Placebo given as a subcutaneous injection, will be given on Day 8 and Day 22 every 28 days starting with Cycle 7 and continuing until disease progression.
Population:
Adult
Last Update
09/16/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer